Abstract
Background: Breast cancer (BC) subtypes exhibit distinct epigenetic landscapes, with triple-negative breast cancer (TNBC) lacking effective targeted therapies. This study investigates histone biomarkers and therapeutic vulnerabilities across BC subtypes. Methods: Immunohistochemical profiling of >20 histone biomarkers, including histone modifications, modifiers and oncohistone mutations was conducted on a discovery cohort and a validation cohort of BC tissues, healthy controls and cell line models. Transcriptomic and cell growth analyses were conducted to evaluate the effects of the small-molecule G9a inhibitor in diverse BC models. Results: Key histone biomarkers, including H3K9me2, H3K36me2, and H3K79me, were differentially expressed across BC subtypes. H3K9me2 emerged as an independent predictor for distinguishing TNBC from other less aggressive BC subtypes, with elevated expression correlating with higher tumor grade and stage. G9a inhibition impaired cell proliferation and modulated epithelial-mesenchymal transition pathways, with the strongest impact in basal-like TNBC. Disruption of oncogene and tumor suppressor regulation (e.g., TP53, SATB1) was observed in TNBC. Conclusion: This study highlights G9a’s context-dependent roles in BC, supporting its potential as a therapeutic target. Findings provide a foundation for subtype-specific epigenetic therapies to improve outcomes in aggressive BC subtypes.
Clinical Perspective
This study was undertaken to explore the epigenetic landscape of breast cancer subtypes, focusing on histone modifications and their therapeutic potential, particularly through targeting G9a, a histone methyltransferase.
The study identified subtype-specific histone biomarkers, with H3K9me2 emerging as a key marker distinguishing TNBC from other less aggressive subtypes. G9a inhibition demonstrated robust anti-cancer effects, including cell proliferation impairment and disruption of oncogenic pathways, particularly in TNBC models.
These findings provide compelling evidence for the development of subtype-specific epigenetic therapies targeting G9a and similar regulators, highlighting their potential to reshape the treatment landscape for TNBC and improve patient outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Natural Science Foundation of China (81672627; 82071863).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study procedures were approved by the Institutional Ethics Committee and the Institutional Review Board of Northwest University (approval number: 200,402,001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw and processed files for RNA sequences (FASTQ format) supporting the findings of this study have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) under accession number GSE283819.
